Form 4: Cadrenal CFO Sells All Direct Shares Under 10b5-1 Plan

Cadrenal Therapeutics' Chief Financial Officer, Matthew K. Szot, sold all 9,933 directly owned shares of common stock for a weighted average price of $6.97 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), sold 9,933 shares of the company's common stock.
• The transaction occurred on December 29, 2025, at a weighted average price of $6.97 per share.
• The sales were executed in multiple transactions at prices ranging from $6.83 through $7.37, inclusive.
• This sale was conducted under a Rule 10b5-1 trading arrangement adopted by Mr. Szot on September 18, 2025.
• Following this transaction, Mr. Szot directly owns 0 shares of Cadrenal Therapeutics common stock.

Sentiment

Score: 2

Explanation: The complete divestment of direct shares by the Chief Financial Officer, even under a pre-arranged 10b5-1 plan, is a significant negative signal, suggesting a lack of long-term conviction in the company's equity by a key insider.

Negatives

• A significant sale of 9,933 shares by the Chief Financial Officer, resulting in zero direct ownership, could be perceived negatively by investors.
• While executed under a 10b5-1 plan, the complete divestment of direct shares by a key insider may signal a lack of long-term conviction in the company's equity.

Risks

• Investor perception risk: The complete sale of direct shares by a key executive could be interpreted by the market as a lack of confidence in the company's future prospects, potentially leading to downward pressure on the stock price.
• Insider selling: The full divestment of direct shares by the CFO might raise questions about long-term alignment with shareholder interests and could precede further negative developments.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction.

Industry Context

This filing reports an insider transaction specific to Cadrenal Therapeutics and its Chief Financial Officer. It does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May interpret the CFO's complete sale of direct shares as a strong negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

The Chief Financial Officer's complete divestment of direct shares, even if pre-planned under a 10b5-1 arrangement, sends a strong negative signal to the market. It suggests a lack of long-term conviction from a key insider, which could precede further declines or indicate underlying issues not yet public. Investors should consider reducing or exiting their position.

Keywords

Cadrenal Therapeutics, CVKD, Form 4, Insider Trading, Stock Sale, Matthew K. Szot, Chief Financial Officer, 10b5-1 Plan, Equity Transaction, Beneficial Ownership